RU2019114208A - Кристаллические формы 4-(2-((1r,2r)-2-гидроксициклогексиламино)бензотиазол-6-илокси)-n-метилпиколинамида - Google Patents
Кристаллические формы 4-(2-((1r,2r)-2-гидроксициклогексиламино)бензотиазол-6-илокси)-n-метилпиколинамида Download PDFInfo
- Publication number
- RU2019114208A RU2019114208A RU2019114208A RU2019114208A RU2019114208A RU 2019114208 A RU2019114208 A RU 2019114208A RU 2019114208 A RU2019114208 A RU 2019114208A RU 2019114208 A RU2019114208 A RU 2019114208A RU 2019114208 A RU2019114208 A RU 2019114208A
- Authority
- RU
- Russia
- Prior art keywords
- value
- wavelength
- measured
- temperature
- cukα radiation
- Prior art date
Links
- -1 BENZOTHIAZOL-6-YLOXY Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 claims 17
- 239000000843 powder Substances 0.000 claims 17
- 230000005855 radiation Effects 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 claims 9
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 claims 7
- IHWOVMRZEIHNGY-SATBOSKTSA-N 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide hydrochloride Chemical compound Cl.O[C@H]1[C@@H](CCCC1)NC=1SC2=C(N1)C=CC(=C2)OC2=CC(=NC=C2)C(=O)NC IHWOVMRZEIHNGY-SATBOSKTSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408358P | 2016-10-14 | 2016-10-14 | |
| US62/408,358 | 2016-10-14 | ||
| PCT/IB2017/056379 WO2018069892A1 (en) | 2016-10-14 | 2017-10-13 | Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019114208A true RU2019114208A (ru) | 2020-11-16 |
| RU2019114208A3 RU2019114208A3 (enExample) | 2020-11-18 |
Family
ID=60320932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019114208A RU2019114208A (ru) | 2016-10-14 | 2017-10-13 | Кристаллические формы 4-(2-((1r,2r)-2-гидроксициклогексиламино)бензотиазол-6-илокси)-n-метилпиколинамида |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10934273B2 (enExample) |
| EP (1) | EP3526217B1 (enExample) |
| JP (1) | JP7068288B2 (enExample) |
| KR (1) | KR20190064589A (enExample) |
| CN (1) | CN109843880B (enExample) |
| AU (1) | AU2017342239B2 (enExample) |
| BR (1) | BR112019006914A2 (enExample) |
| CA (1) | CA3039764A1 (enExample) |
| CL (1) | CL2019001008A1 (enExample) |
| ES (1) | ES2949414T3 (enExample) |
| IL (1) | IL265893A (enExample) |
| MX (1) | MX2019004345A (enExample) |
| RU (1) | RU2019114208A (enExample) |
| WO (1) | WO2018069892A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| CA3162315A1 (en) * | 2019-12-20 | 2021-06-24 | Marinus Jacobus Verwijs | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101432281B (zh) * | 2006-04-19 | 2013-08-28 | 诺瓦提斯公司 | 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
| PE20080359A1 (es) * | 2006-04-19 | 2008-06-06 | Novartis Ag | Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r |
| CA2834696C (en) * | 2011-05-05 | 2019-07-23 | Novartis Ag | Csf-1r inhibitors for treatment of brain tumors |
| WO2016100882A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
-
2017
- 2017-10-13 AU AU2017342239A patent/AU2017342239B2/en not_active Ceased
- 2017-10-13 BR BR112019006914A patent/BR112019006914A2/pt not_active IP Right Cessation
- 2017-10-13 KR KR1020197010527A patent/KR20190064589A/ko not_active Ceased
- 2017-10-13 RU RU2019114208A patent/RU2019114208A/ru not_active Application Discontinuation
- 2017-10-13 JP JP2019520040A patent/JP7068288B2/ja active Active
- 2017-10-13 EP EP17797745.1A patent/EP3526217B1/en active Active
- 2017-10-13 ES ES17797745T patent/ES2949414T3/es active Active
- 2017-10-13 WO PCT/IB2017/056379 patent/WO2018069892A1/en not_active Ceased
- 2017-10-13 US US16/341,124 patent/US10934273B2/en active Active
- 2017-10-13 CA CA3039764A patent/CA3039764A1/en not_active Abandoned
- 2017-10-13 MX MX2019004345A patent/MX2019004345A/es unknown
- 2017-10-13 CN CN201780063254.XA patent/CN109843880B/zh active Active
-
2019
- 2019-04-07 IL IL265893A patent/IL265893A/en unknown
- 2019-04-12 CL CL2019001008A patent/CL2019001008A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109843880A (zh) | 2019-06-04 |
| EP3526217A1 (en) | 2019-08-21 |
| US20200190057A1 (en) | 2020-06-18 |
| IL265893A (en) | 2019-06-30 |
| CN109843880B (zh) | 2023-12-01 |
| WO2018069892A1 (en) | 2018-04-19 |
| RU2019114208A3 (enExample) | 2020-11-18 |
| JP2019530719A (ja) | 2019-10-24 |
| EP3526217B1 (en) | 2023-04-19 |
| CL2019001008A1 (es) | 2019-06-21 |
| CA3039764A1 (en) | 2018-04-19 |
| KR20190064589A (ko) | 2019-06-10 |
| AU2017342239B2 (en) | 2020-05-28 |
| JP7068288B2 (ja) | 2022-05-16 |
| BR112019006914A2 (pt) | 2019-07-02 |
| US10934273B2 (en) | 2021-03-02 |
| ES2949414T3 (es) | 2023-09-28 |
| MX2019004345A (es) | 2019-07-01 |
| AU2017342239A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| JP2014525470A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| EP4563150A3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| JP2015512942A5 (enExample) | ||
| RU2599785C3 (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| RU2017111590A (ru) | Кристаллические формы 2-(4-(4-этокси-6-оксо-1,6-дигидропиридин-3-ил)-2-фторфенил)-n-(5-(1,1,1-трифтор-2- метилпропан-2-ил)изоксазол-3-ил)ацетамида | |
| UA129695C2 (uk) | Спосіб отримання та кристалічні форми проміжного продукту в синтезі інгібітора mdm2 | |
| RU2010133483A (ru) | Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты | |
| MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| RU2014145544A (ru) | Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека | |
| JP2016503010A5 (enExample) | ||
| HRP20190815T1 (hr) | Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret) | |
| RU2017107760A (ru) | Соединение | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2015106137A (ru) | Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения | |
| JP2018531280A5 (enExample) | ||
| JP2015522589A5 (enExample) | ||
| RU2019105794A (ru) | Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат | |
| JP2016513704A5 (enExample) | ||
| RU2016141650A (ru) | Амидные соединения | |
| JP2015193630A5 (enExample) | ||
| RU2007133802A (ru) | Кристаллические формы производной имидазола |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210830 |